Market Research Logo

Global Hyperphosphatemia Drugs Market 2015-2019

Global Hyperphosphatemia Drugs Market 2015-2019

About hyperphosphatemia

Phosphorus is an important element for normal physiologic functions such as bone construction, nerve function, and muscle contraction. About 85% of phosphorus is stored in the bones and different tissues in the body. The excess phosphorus is eliminated from the body by the urinary system. The normal phosphate level in the blood is 3-4 mg/dL. Electrolytic disturbance resulting in high levels of phosphate in the blood causes hyperphosphatemia. Individuals with chronic kidney diseases have a decreased glomerular filtration rate and increased serum phosphate levels. The high phosphate levels in the serum lower calcium levels because of phosphate precipitation by calcium ions, leading to calcification of vascular tissues and heart diseases. Aluminum-, calcium-, magnesium-, and iron-based and aluminum-free, calcium-free phosphate binders are used to treat the condition.

Technavio's analysts forecast the global hyperphosphatemia drugs market to grow at a CAGR of 10.71% over the period 2014-2019.

Covered in this Report

In this report, Technavio covers the present scenario and growth prospects of the global hyperphosphatemia drugs market for 2015-2019. To calculate the market size, the report considers revenue generated from the sales of branded, generic, OTC, and off-label drugs used for treating hyperphosphatemia.

Technavio's report, Global Hyperphosphatemia Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global hyperphosphatemia drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.Key regions

  • Americas
  • APAC
  • EMEA
Key vendors
  • Fresenius Medical Care
  • Keryx Biopharmaceuticals
  • Sanofi
  • Shire
  • Vifor Pharma
Other prominent vendors
  • Alkem
  • Amgen
  • Ardelyx
  • AstraZeneca
  • Baxter
  • Bayer
  • Chugai Pharmaceutical
  • Japan Tobacco
  • Kissei Pharmaceutical
  • Kyowa Hakko Kirin
  • Mylan
  • Natco
  • Novartis
  • Opko Health
  • Panion & BF Biotech
  • Roxane Laboratories
  • Sandoz
  • Synthon
  • Torri Pharmaceutical
Market driver
  • Increased number of people undergoing dialysis
  • For a full, detailed list, view our report
Market challenge
  • Non-adherence to treatment regimens
  • For a full, detailed list, view our report
Market trend
  • Patient assistance programs
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Hyperphosphatemia Drugs Market 2015-2019

Technavio recognizes the following companies as the key players in the Global Hyperphosphatemia Drugs Market: Fresenius Medical Care, Keryx Biopharmaceuticals, Sanofi, Shire and Vifor Pharma

The other prominent vendors are: Alkem, Amgen, Ardelyx, AstraZeneca, Baxter, Bayer, Chugai Pharmaceutical, Japan Tobacco, Kissei Pharmaceutical, Kyowa Hakko Kirin, Mylan, Natco, Novartis, Opko Health, Panion & BF Biotech, Roxane Laboratories, Sandoz, Synthon and Torri Pharmaceutical

Commenting on the report, an analyst from Technavio’s team said: “The market presents huge growth opportunities for vendors because of the growing incidence of hyperphosphatemia and associated high pill burden. Currently, many companies are investing in the discovery and R&D of drugs for the condition. For instance, Tenapor by Ardelyx and AstraZeneca is in phase II developmental stage. The entry of this drug will likely reduce the pill burden associated with the condition. Similarly, RDX002, a type 2a sodium phosphate cotransporter (NaP2b) inhibitor, is being developed by Sanofi. Ardelyx licensed the drug to Sanofi, but retained its co-promotion rights in the US. The launch of novel drug candidates with higher efficacy and safety profile, currently under different stages of development, will contribute to market growth.”

According to the report, diabetes and hypertension are the main causes of renal failure, which in turn leads to hyperphosphatemia. The USRDS reported in 2014 that 13.6% adults in the US had CKD, of which diabetes accounted for 44% of kidney failure cases. It also reported in 2012 that high blood pressure led to an increase of 7.7% of kidney failure cases from 2000 to 2010. The International Diabetes Federation reported in 2014 that 387 million people had diabetes in the same year, which is expected to increase by 2035. WHO reported in 2013 that currently over 1 billion people have high blood pressure and about 9.4 million people die from the condition annually worldwide.

Further, the report states that non-adherence to treatment regimens is a major challenge faced by the market.

Companies Mentioned

Fresenius Medical Care, Keryx Biopharmaceuticals, Sanofi, Shire, Vifor Pharma, Alkem, Amgen, Ardelyx, AstraZeneca, Baxter, Bayer, Chugai Pharmaceutical, Japan Tobacco, Kissei Pharmaceutical, Kyowa Hakko Kirin, Mylan, Natco, Novartis, Opko Health, Panion & BF Biotech, Roxane Laboratories, Sandoz, Synthon, Torri Pharmaceutical

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Product profiles
  • Introduction
    • Key market highlights
  • Disease Overview
    • Understanding the disease
    • Etiology
      • Table Pathophysiology of hyperphosphatemia
    • Effects of hyperphosphatemia
      • Table Effects of hyperphosphatemia
    • Causes
    • Signs and symptoms
    • Diagnosis
      • Table Differential diagnosis of hyperphosphatemia
    • Management
      • Table Ideal characteristics of phosphate binders
      • Table Advantages and disadvantages of different phosphate binders
    • Epidemiology
      • Table Prevalence of CKD among participants by CKD stage in US 1988-2012
      • Table Number of dialysis patients worldwide 2012-2014 (millions)
  • Key developments in hyperphosphate mia therapy
  • Guidelines for use of phosphate binders
    • CKD stages 2-4
    • CKD stage 5
  • Pipeline analysis
    • Table Pipeline portfolio of hyperphosphatemia drugs
    • Information on pipeline candidates
  • Market landscape
    • Market overview
    • Market size and forecast
      • Table Global hyperphosphatemia drugs market 2014-2019 ($ millions)
    • Five forces analysis
      • Table Five forces analysis
  • Hyperphosphate mia management market dynamics
    • Table Market dynamics of phosphate binders for hyperphosphatemia
  • Market segmentation by dosage form
    • Table Segmentation of global hyperphosphatemia drugs market by dosage form
    • Solid
    • Liquid
  • Market segmentation by formulation
    • Table Segmentation of global hyperphosphatemia drugs market by formulation
    • Aluminum-based phosphate binders
    • Calcium-based phosphate binders
    • Aluminum-free, calcium-free phosphate binder
    • Magnesium-based phosphate binders
    • Iron-based phosphate binders
  • Geographical segmentation
    • Global hyperphosphatemia drugs market segmentation by geography
      • Table Global hyperphosphatemia drugs market segmentation by geography 2014
      • Table Global hyperphosphatemia drugs market segmentation by geography 2014-2019 ($ millions)
    • Hyperphosphatemia drugs market in Americas
      • Table Hyperphosphatemia drugs market in Americas 2014-2019 ($ millions)
    • Hyperphosphatemia drugs market in EMEA
      • Table Hyperphosphatemia drugs market in EMEA 2014-2019 ($ millions)
    • Hyperphosphatemia drugs market in APAC
      • Table Hyperphosphatemia drugs market in APAC 2014-2019 ($ millions)
  • Key leading countries
    • Key leading countries
      • Hyperphosphatemia drugs market in the US
        • Table Hyperphosphatemia drugs market in the US 2014-2019 ($ millions)
    • Hyperphosphatemia drugs market in Japan
      • Table Hyperphosphatemia drugs market in Japan 2014-2019 ($ millions)
  • Market drivers
    • Table Number of individuals who underwent dialysis by region 2012-2014
    • Table Percentage of individuals who underwent dialysis by region 2012-2014
    • Table Global prevalence of diabetes 2014 and 2035 (millions)
    • Table Worldwide population aged 80 and above 1950-2050 (millions)
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Table Rate of adherence to phosphate binders
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Table R&D expenses by Auryxia 2012-2014 ($)
  • Vendor landscape
    • Competitive scenario
    • Market share analysis 2014
      • Table Global hyperphosphatemia market share analysis 2014
      • Table Ranking of vendors in market
      • Table Sanofi: YoY growth and revenue of Renagel and Renvela 2011-2014 ($ millions)
      • Table Sanofi: Revenue of Renagel and Renvela by region 2011-2014 ($ millions)
      • Table FOSRENOL: YoY growth and revenue of FOSRENOL except Japan 2011-2014 ($ millions)
    • Brand differentiation
      • Table Brand differentiation of phosphate binders by major vendors
    • Other prominent vendors
  • Key vendor analysis
    • Fresenius Medical Care
      • Table Fresenius: Business segmentation by revenue 2014
      • Table Fresenius: Business segmentation by revenue 2013 and 2014 ($ billions)
      • Table Fresenius: Geographical segmentation by revenue 2014
    • Keryx Biopharmaceuticals
    • Sanofi
      • Table Sanofi: Business segmentation 2014
      • Table Sanofi: Business segmentation by revenue 2014
      • Table Sanofi: Business segmentation by revenue 2013 and 2014 ($ billions)
      • Table Sanofi: Geographical segmentation by revenue 2014
    • Shire
      • Table Shire: Product segmentation by revenue 2014
      • Table Shire: Business segmentation by revenue 2013 and 2014 ($ billions)
      • Table Shire: Geographical segmentation by revenue 2014
    • Vifor Pharma
      • Table Vifor Pharma: Product segmentation
  • Appendix
    • List of abbreviation
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report